Alto Neuroscience(US:ANRO) Prnewswireยท2025-09-18 12:45Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) due to allegations of misleading statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder [2]. Group 1: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [1]. - Shareholders are encouraged to register for the class action by September 19, 2025, to potentially be appointed as lead plaintiff [3]. Group 2: Allegations Against the Company - The complaint alleges that the company misrepresented the effectiveness of ALTO-100, overstating its clinical, regulatory, and commercial prospects [2]. - As a result of these misrepresentations, the company's business and financial prospects were also overstated, leading to materially false and misleading public statements [2]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [4].